<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639756</url>
  </required_header>
  <id_info>
    <org_study_id>IbSalut-M-001</org_study_id>
    <nct_id>NCT00639756</nct_id>
  </id_info>
  <brief_title>The Effect of Allopurinol on Insulin Resistance and Blood Pressure</brief_title>
  <official_title>Phase 2 Study to Determine if Allopurinol Blocks Features of Metabolic Syndrome Induced by Fructose Ingestion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Mateo Orfila</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Mateo Orfila</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies in animals have found that allopurinol can markedly improve fructose induced
      metabolic syndrome. In this study we test the hypothesis that allopurinol may lower BP,
      reduce triglycerides, and improve metabolic parameters in subjects placed on a high fructose
      diet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 male subjects, age 40 to 65 years of age, will be placed on a 3500kcal (55% carbohydrates
      containing 200 g fructose) for 2 weeks. Half will receive allopurinol mg/day (randomized). At
      the end of 2 weeks we measure a variety of parameters including fasting glucose and insulin
      levels (with calculation of HOMA index), serum lipids (including triglycerides and LDL/HDL
      cholesterol), sitting blood pressure, serum uric acid, weight, and various other measurements
      (C reactive protein, adiponectin and leptin levels, and urate redox products). Primary
      endpoint is insulin resistance. Secondary endpoints are blood pressure, lipids, uric acid,
      weight.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance (HOMA index)</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides, HDL cholesterol</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP level</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol given for 2 weeks with diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol 300 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given for 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males, age 40 -65 yrs

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Renal Unit, Mateo Orfila Hospital</name>
      <address>
        <city>Menorca</city>
        <state>Balearic Islands</state>
        <zip>07703</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>October 10, 2008</last_update_submitted>
  <last_update_submitted_qc>October 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>PEREZ-POZO, SANTOS E. LOPEZ-LILLO, JULIAN. JOHNSON, RICHARD</name_title>
    <organization>MATEO ORFILA HOSPITAL, University of Florida</organization>
  </responsible_party>
  <keyword>Uric acid</keyword>
  <keyword>Fructose</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glucose</keyword>
  <keyword>HOMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

